Key Points
- Casdin Capital bought 50,000 more GeneDx shares at an average price of $52.86, bringing its total ownership to 3,707,164 shares. The firm has been steadily accumulating shares with several recent purchases in May and June.
- GeneDx stock was down 0.8% and opened at $51.80, well below its 52-week high of $170.87. The company’s shares also trade under both the 50-day and 200-day moving averages.
- Analysts remain mixed but generally constructive, with GeneDx holding an average rating of Moderate Buy and a consensus price target of $96.43. However, the company also faces legal overhang from securities class-action litigation related to prior disclosures and a sharp selloff.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) Director Casdin Capital, Llc acquired 50,000 shares of the firm's stock in a transaction on Friday, June 5th. The stock was purchased at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the purchase, the director owned 3,707,164 shares of the company's stock, valued at $195,960,689.04. The trade was a 1.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Casdin Capital, Llc also recently made the following trade(s):
- On Thursday, June 4th, Casdin Capital, Llc acquired 150,000 shares of GeneDx stock. The stock was purchased at an average cost of $56.44 per share, with a total value of $8,466,000.00.
- On Wednesday, May 20th, Casdin Capital, Llc bought 140,000 shares of GeneDx stock. The stock was bought at an average price of $43.81 per share, for a total transaction of $6,133,400.00.
- On Tuesday, May 19th, Casdin Capital, Llc bought 185,000 shares of GeneDx stock. The shares were bought at an average cost of $42.60 per share, for a total transaction of $7,881,000.00.
- On Monday, May 18th, Casdin Capital, Llc purchased 175,000 shares of GeneDx stock. The shares were bought at an average cost of $42.55 per share, with a total value of $7,446,250.00.
GeneDx Stock Down 0.8%
Shares of NASDAQ WGS opened at $51.80 on Tuesday. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -19.33 and a beta of 1.96. The stock has a 50 day moving average price of $55.25 and a 200 day moving average price of $92.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09.
GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to analysts' expectations of $112.46 million. During the same quarter in the previous year, the business earned ($0.23) earnings per share. Sell-side analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Weiss Ratings cut GeneDx from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, June 1st. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research note on Monday, February 23rd. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a "buy" rating in a research report on Tuesday, May 5th. Wells Fargo & Company reiterated an "overweight" rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered shares of GeneDx from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $96.43.
Get Our Latest Research Report on WGS
Institutional Investors Weigh In On GeneDx
A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company's stock worth $2,611,000 after acquiring an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company's stock valued at $677,000 after purchasing an additional 453 shares during the period. NewEdge Advisors LLC raised its stake in shares of GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company's stock worth $240,000 after purchasing an additional 2,707 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company's stock worth $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in shares of GeneDx during the second quarter worth about $249,000. 61.72% of the stock is owned by hedge funds and other institutional investors.
GeneDx News Summary
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
- Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
- Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
- Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
- Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article
GeneDx Company Profile
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
